Exploring the Efficacy of Modified Folfirinox in Pancreatic Cancer Treatment

This chapter explores the Modified Folfirinox regimen for pancreatic cancer as presented at the ASCO conference and published in the New England Journal of Medicine. It discusses the historical context of adjuvant therapies, the PRODIGE 24 study findings, and the complexities involved in administering this chemotherapy regimen.